Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 24:2022:9961412.
doi: 10.1155/2022/9961412. eCollection 2022.

Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer

Xiaoqin Li  1   2 , Xinyue Tang  1 , Kunsong Li  1 , Ling Lu  3
Affiliations

Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer

Xiaoqin Li et al. Biomed Res Int. .

Abstract

Background: MicroRNAs (miRNAs) play important roles in the initiation and progression of cancers. The purpose of the present study was to evaluate the use of serum miRNA biomarkers in the early diagnosis of breast cancer.

Methods: The expression levels of miR-9-5p, miR-17-5p, and miR-148a-3p were analyzed by quantitative reverse transcription-polymerase chain reaction in 49 patients with newly diagnosed breast cancer and 49 healthy controls. The associations between miR-9-5p, miR-17-5p, and miR-148a-3p levels and clinicopathological parameters were also analyzed. Regression analysis and sensitivity and specificity analyses were used to determine the diagnostic efficacy of the miRNAs.

Results: Serum levels of miR-9-5p and miR-148a-3p were significantly higher in breast cancer patients than in healthy controls (both P < 0.05), but miR-17-5p levels were not different between the two groups (P = 0.996). Serum miR-9-5p levels were markedly higher in patients with human epidermal growth factor receptor 2- (HER2-) positive breast cancer than in those with HER2-negative breast cancer (P = 0.049). Serum levels of miR-9-5p and miR-148a-3p were positively correlated with the presence of breast cancer, and both miRNAs had high sensitivity and specificity for the diagnosis of breast cancer.

Conclusions: These findings provide evidence that serum miR-9-5p and miR-148a-3p levels may be used as noninvasive biological markers for the clinical diagnosis of breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Serum levels of the three microRNA candidates in the case and control groups.
See this image and copyright information in PMC

References

    1. Torre L. A., Siegel R. L., Ward E. M., Jemal A. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiology, Biomarkers & Prevention . 2016;25(1):16–27. doi: 10.1158/1055-9965.EPI-15-0578. - DOI - PubMed
    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2019. CA: a Cancer Journal for Clinicians . 2019;69(1):7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Lei S., Zheng R., Zhang S., et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Communications . 2021;41(11):1183–1194. doi: 10.1002/cac2.12207. - DOI - PMC - PubMed
    1. Takahashi T. A., Lee C. I., Johnson K. M. Breast cancer screening: does tomosynthesis augment mammography? Cleveland Clinic Journal of Medicine . 2017;84(7):522–527. doi: 10.3949/ccjm.84a.16057. - DOI - PubMed
    1. Manca G., Tardelli E., Rubello D., et al. Sentinel lymph node biopsy in breast cancer. Nuclear Medicine Communications . 2016;37(6):570–576. doi: 10.1097/MNM.0000000000000489. - DOI - PubMed